SCHEMBL3769780

SCHEMBL3769780

O=C(CN1CCN(c2cc(C(F)(F)F)ccn2)CC1)N1CCN(C2CCCC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
MAPT P10636 4/20 0.51
NPSR1 Q6W5P4 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
FFAR4 Q5NUL3 1/20 0.48
HRH3 Q9Y5N1 2/20 0.47
LMNA P02545 2/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TRPV1 Q8NER1 2/20 0.45
PPARG P37231 1/20 0.45
PPARD Q03181 1/20 0.45
PPARA Q07869 1/20 0.45
ADRB1 P08588 1/20 0.45
KDM4E B2RXH2 3/20 0.44
TSHR P16473 2/20 0.44
ALOX12 P18054 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773673 0.86 SMN1; SMN2 (0.54) ALDH1A1MAPTNPSR1MEN1KMT2A
SCHEMBL3777238 0.85 SMN1; SMN2 (0.53) ALDH1A1MAPTNPSR1MEN1KMT2A
SCHEMBL3771336 0.84 SMN1; SMN2 (0.54) ALDH1A1MAPTNPSR1MEN1KMT2A
SCHEMBL3773978 0.82 POLB (0.60) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL3763137 0.81 ME2 (0.55) ALDH1A1MAPTNPSR1MEN1KMT2A
SCHEMBL13004950 0.81 ALDH1A1 (0.63) ALDH1A1MAPTNPSR1KMT2ASMN1; SMN2
SCHEMBL3769985 0.81 POLB (0.59) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL3769215 0.80 ME2 (0.54) ALDH1A1MAPTNPSR1MEN1KMT2A
SCHEMBL3762865 0.80 POLB (0.61) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL3768241 0.79 SMN1; SMN2 (0.82) ALDH1A1MAPTNPSR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885MAPT 1475/4885NPSR1 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.